×
Saturday, January 28, 2023

First Human Clinical Trial Proves TruZen® CBD Formula with Patented VESIsorb® Technology Achieves 360% gr - Benzinga

FOR ONLY $0.99: During this bear market you can follow full-time trader Chris Capre & get his options trades signals in real-time. Click Here to See His Next Trade!

TruZen Health has announced the results of a first ever human-based clinical trial, proving its proprietary TruZen CBD formula with patented VESIsorb Technology achieves 360% greater bioavailability of β-caryophyllene (BCP).

PITTSBURGH, Nov. 30, 2022 /PRNewswire-PRWeb/ -- Nutraceuticals Innovator TruZen Health has announced the results of a first ever human-based clinical trial, proving its proprietary TruZen CBD formula with patented VESIsorb Technology achieves 360% greater bioavailability of β-caryophyllene (BCP).

This is how you can potentially earn extra income every single month...

Former leading hedge-fund trader Chris Capre is the real deal. With his simple options trading strategy, he's helping thousands of traders by sharing his trade signals in real-time. Click Here to get his Trades for only $0.99. "My only regret is I wish I joined earlier..."

BCP is a natural bicyclic sesquiterpene and a common constituent of the essential oils of numerous food plants such as hemp (Cannabis sativa L) and is thought to interact with the endocannabinoid system by binding selectively to cannabinoid receptors type 2 (CB2). Decades of preclinical research have investigated the potential therapeutic benefits of BCP, such as analgesic, anti-inflammatory, and anti-depressive.

The clinical trial, a randomized,...



source: https://news.google.com/__i/rss/rd/articles/CBMimQFodHRwczovL3d3dy5iZW56aW5nYS5jb20vcHJlc3NyZWxlYXNlcy8yMi8xMS9uMjk5MTI2OTUvZmlyc3QtaHVtYW4tY2xpbmljYWwtdHJpYWwtcHJvdmVzLXRydXplbi1jYmQtZm9ybXVsYS13aXRoLXBhdGVudGVkLXZlc2lzb3JiLXRlY2hub2xvZ3ktYWNoaWV2ZXMtMzbSAS1odHRwczovL3d3dy5iZW56aW5nYS5jb20vYW1wL2NvbnRlbnQvMjk5MTI2OTU?oc=5